Teladoc Health (NYSE:TDOC) PT Lowered to $28.00

Teladoc Health (NYSE:TDOC – Get Rating) had its price objective dropped by stock analysts at Barclays from $32.00 to $28.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently has an “equal weight” rating on the health services provider’s stock. Barclays‘s target price would suggest a potential upside of 12.31% from the stock’s previous close.

Several other equities research analysts have also commented on TDOC. Canaccord Genuity Group lowered their price objective on Teladoc Health from $45.00 to $43.00 in a research report on Friday, October 28th. Royal Bank of Canada lowered their price objective on Teladoc Health from $53.00 to $35.00 in a research report on Wednesday, September 28th. Guggenheim upgraded Teladoc Health from a “sell” rating to a “neutral” rating in a research report on Monday, October 24th. Deutsche Bank Aktiengesellschaft reduced their target price on Teladoc Health from $34.00 to $31.00 and set a “hold” rating for the company in a research note on Tuesday, September 27th. Finally, DA Davidson reduced their target price on Teladoc Health from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, October 25th. One analyst has rated the stock with a sell rating, twenty-two have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $47.79.

Teladoc Health Price Performance

Shares of NYSE TDOC opened at $24.93 on Wednesday. The business’s 50 day moving average price is $26.59 and its 200 day moving average price is $30.36. The firm has a market cap of $4.04 billion, a P/E ratio of -0.41 and a beta of 0.98. Teladoc Health has a 52 week low of $21.60 and a 52 week high of $82.99. The company has a quick ratio of 2.99, a current ratio of 3.13 and a debt-to-equity ratio of 0.25.

Teladoc Health (NYSE:TDOC – Get Rating) last issued its earnings results on Wednesday, October 26th. The health services provider reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.14. Teladoc Health had a negative return on equity of 2.47% and a negative net margin of 424.40%. The firm had revenue of $611.40 million for the quarter, compared to analyst estimates of $609.45 million. On average, sell-side analysts expect that Teladoc Health will post -1.4 earnings per share for the current year.

Insider Buying and Selling at Teladoc Health

In other news, SVP Daniel Trencher sold 1,000 shares of the stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $26.80, for a total transaction of $26,800.00. Following the completion of the transaction, the senior vice president now directly owns 21,408 shares in the company, valued at approximately $573,734.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, SVP Daniel Trencher sold 1,000 shares of the stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $26.80, for a total transaction of $26,800.00. Following the completion of the transaction, the senior vice president now directly owns 21,408 shares in the company, valued at approximately $573,734.40. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Arnnon Geshuri sold 2,398 shares of the stock in a transaction on Monday, November 28th. The stock was sold at an average price of $27.35, for a total value of $65,585.30. Following the transaction, the insider now owns 74,317 shares of the company’s stock, valued at $2,032,569.95. The disclosure for this sale can be found here. Insiders have sold 3,925 shares of company stock worth $107,958 over the last quarter. 1.55% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teladoc Health

Hedge funds have recently modified their holdings of the business. Activest Wealth Management lifted its stake in Teladoc Health by 270.5% during the 3rd quarter. Activest Wealth Management now owns 678 shares of the health services provider’s stock worth $26,000 after acquiring an additional 495 shares in the last quarter. Oliver Lagore Vanvalin Investment Group lifted its stake in Teladoc Health by 94.3% during the 3rd quarter. Oliver Lagore Vanvalin Investment Group now owns 1,030 shares of the health services provider’s stock worth $26,000 after acquiring an additional 500 shares in the last quarter. SeaCrest Wealth Management LLC acquired a new position in Teladoc Health during the 2nd quarter worth about $28,000. Bank Julius Baer & Co. Ltd Zurich lifted its stake in Teladoc Health by 962.0% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,062 shares of the health services provider’s stock worth $35,000 after acquiring an additional 962 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in Teladoc Health by 23.3% during the 2nd quarter. Quadrant Capital Group LLC now owns 1,385 shares of the health services provider’s stock worth $46,000 after acquiring an additional 262 shares in the last quarter. 84.14% of the stock is currently owned by hedge funds and other institutional investors.

About Teladoc Health

(Get Rating)

Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.